Acumen Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: Probability-weighted (rNPV-style) scenario valuation ahead of the late-2026 Phase 2 sabirnetug (ALTITUDE-AD) Alzheimer's readout: 35% probability of a positive readout valued at $8.24/share (based on a ~$700 million re-rated market cap on ~85 million diluted shares after an assumed post-data raise) and 65% probability of a negative readout valued at $0.69/share (a cash-floor value using the $110.2 million June 30 2026 cash/marketable-securities balance net of wind-down costs on 72.32 million shares); expected value discounted 0.25 years at a 12% required return.

Reasoning: Acumen is a pre-revenue clinical-stage biotech with a single near-term binary catalyst and no cash flows to discount, so a decision-tree/risk-adjusted NPV approach anchored to the trial outcome and net cash is the only rigorous, explicit method available, rather than a conventional FCF DCF.